Line 4: |
Line 4: |
| {{Under Construction}} | | {{Under Construction}} |
| | | |
− | <blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-30. The original page can be found at [[HAEM4:Gamma Heavy Chain Disease]]. | + | <blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-12-04. The original page can be found at [[HAEM4:Gamma Heavy Chain Disease]]. |
| }}</blockquote> | | }}</blockquote> |
| ==Primary Author(s)*== | | ==Primary Author(s)*== |
Line 19: |
Line 19: |
| ==Cancer Category / Type== | | ==Cancer Category / Type== |
| | | |
− | *[[Mature B-Cell Neoplasms]] | + | *[[HAEM4:Mature B-Cell Neoplasms]] |
| | | |
| ==Cancer Sub-Classification / Subtype== | | ==Cancer Sub-Classification / Subtype== |
Line 355: |
Line 355: |
| Some cases of gamma-HCD (γ-HCD) are concurrent with other lymphoid neoplasm have been reported in the literature and are listed below; treatment option varies with concurrent neoplasm | | Some cases of gamma-HCD (γ-HCD) are concurrent with other lymphoid neoplasm have been reported in the literature and are listed below; treatment option varies with concurrent neoplasm |
| | | |
− | *[[Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL)]] | + | *[[HAEM5:Chronic lymphocytic leukaemia/small lymphocytic lymphoma|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL)]] |
| *DLBCL-diffuse large B cell Lymphoma | | *DLBCL-diffuse large B cell Lymphoma |
| *LCPD-lymphoplasma cell proliferative disorder | | *LCPD-lymphoplasma cell proliferative disorder |
− | *[[Lymphoplasmacytic Lymphoma|Lymphoplasmacytic Lymphoma (LPL]]) | + | *[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic Lymphoma (LPL]]) |
| *MALT -mucosa-associated lymphoid tissue | | *MALT -mucosa-associated lymphoid tissue |
| *MDS-myelodysplastic syndrome | | *MDS-myelodysplastic syndrome |